UPDATE 1-SciClone Q3 tops estimates, raises '09 view
2009-11-09 07:47:00.0
UPDATE 1-SciClone Q3 tops estimates, raises '09 view | Reuters
Track China's Leaders
UPDATE 1-SciClone Q3 tops estimates, raises '09 view
Mon, Nov 9 2009
Mon, Nov 9 2009
Fri, Nov 6 2009
Thu, Nov 5 2009
Wed, Nov 4 2009
Mon  EST
* Raises '09 profit and rev view
) posted a better-than-expected quarterly profit on strong sales of its hepatitis B treatment and lower research and development expenses, and raised its 2009 forecast.
Third-quarter net income was $2.1 million, or 4 cents a share, compared to $773,000, or 2 cents a share, in the year-ago period. [ID:nWNAB2726]
Analysts were expecting earnings of 1 cent, on revenue of $16.8 million, according to Thomson Reuters I/B/E/S.
For 2009, the company now expects to earn 18 cents to 22 cents a share, up from its prior view of 10 cents to 14 cents.
Revenue is expected to be between $70 million and $72 million, compared to its previous expectation of $69 million to $71 million.
SciClone sells Zadaxin, a drug approved in China and other overseas markets, to treat hepatitis B infections and to boost the immune systems of other patients, including those with liver cancer.
Shares of the Forest City, California-based company closed at $2.95 Friday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Aradhana Aravindan)
